Recomendaciones de Vacunación Antineumocócica en el Adulto por Indicación Médica

Documento de consenso de las Sociedades Científicas de Medicina Preventiva: Sociedad Española de Medicina Preventiva, viagra 100mg Salud Pública e Higiene; Sociedad Gallega de Medicina Preventiva; Societat Valenciana de Medicina Preventiva i Salut Pública; Sociedad Norte de Medicina Preventiva y Salud Pública; Sociedad Canaria de Medicina Preventiva Hospitalaria; Sociedad Andaluza de Medicina Preventiva; Sociedad Madrileña de Medicina Preventiva; Sociedad Castellano Manchega de Medicina Preventiva y Salud Pública. Con la colaboración del CNM-ISCIII.

30092012 Recom Vac Antineumocócica SEMPSPH vers final

Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older

MMWR. Weekly

June 1, 2012 / 61(21);394-395
In 2010, 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.]) was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP) for children aged 6 weeks through 71 months for the prevention of invasive pneumococcal disease (IPD) caused by the 13 pneumococcal serotypes included in the vaccine. PCV13 currently is recommended as a 4-dose series for children starting at age 2 months. On December 30, 2011, FDA approved PCV13 for prevention of pneumonia and invasive disease caused by PCV13 serotypes among adults aged 50 years and older. This report summarizes data on the immunogenicity and safety of PCV13 in adults and outlines key additional evidence requested by ACIP to formulate recommendations for its use. Leer más